The objective of this study was to study the effect of CYP2C9 genetic polymorphism and
undernourishment on free phenytoin concentrations in epileptic patients. The study was …

Background Epilepsy is a serious health problem worldwide. Despite the introduction of new
antiepileptic drugs (AEDs) almost 30% of these patients have drug-resistant forms of the …

Abstract Background The cytochrome P450 (CYP) isoenzymes have an indispensable role
in the metabolic phase of different medications during the treatment of multiple …

Objective To examine the genetic polymorphism of CYP2C9 and CYP2C19 and its effect on
the pharmacokinetics of phenytoin among 44 Japanese patients with epilepsy. Methods …

Background Phenytoin, mainly metabolized by cytochrome P450 enzyme system, has a
narrow therapeutic index and may have adverse effects due to inter-individual variation in …

Introduction: Phenytoin, a widely prescribed old-generation antiepileptic drug, requires
careful individualization of dosage to compensate for its prominent pharmacokinetic …

Objective: Therapeutic response to phenytoin (PHT), a first-line antiepileptic drug (AED), is
highly variable, in part likely due to genetic factors. Genetic polymorphisms in cytochrome …

CYP2C9 is the key enzyme in aromatic antiepileptic drugs (AEDs) metabolism. CYP2C9* 3
is a loss of function polymorphism. This study was designed to investigate genetic …

Epilepsy is characterized by repeated seizure activity. Valproate, a commonly used
antiepileptic drug, shows large inter-individual variation in plasma valproic levels and …

Although aromatic anticonvulsants are usually well tolerated, they can cause cutaneous
adverse drug reactions in up to 10% of patients. The clinical manifestations of the …